BIRC3 and B-cell chronic lymphocytic leukemia: Notably, primary CLL samples derived from patients carrying BIRC3 mutations (n = 3) or NOTCH1 mutations (n = 1) in their CLL tumor cells were particularly sensitive to NIK inhibition (Figure 2A).